Holen Sie sich die Stockscreener-App
34.84
2.71%
0.92
Handel nachbörslich:
34.84
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
How does Spyre Therapeutics Inc score in quality rankingsGDP Growth & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Candriam S.C.A. - MarketBeat
Risks Report: Is Spyre Therapeutics Inc. benefiting from interest rate changesJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru
Aug Final Week: Is Spyre Therapeutics Inc stock a hidden gemJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Short Interest in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Drops By 13.5% - Defense World
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Turtle Cameron, Spyre Therapeutics CEO, sells shares worth $492k By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Significant Decrease in Short Interest - MarketBeat
AlphaQuest LLC Purchases 61,989 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
VIX Spike: Is SOUNW a cyclical or defensive stockJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - baoquankhu1.vn
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Biotechnology Innovator with 68% Upside Potential - DirectorsTalk Interviews
Nasdaq Moves: How does Spyre Therapeutics Inc score in quality rankingsCEO Change & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Review: Is Spyre Therapeutics Incs ROIC above industry averagePrice Action & Weekly Top Performers Watchlists - baoquankhu1.vn
Is Spyre Therapeutics Incs ROIC above industry averageJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
Spyre’s new commercial chief granted 108K stock options at $34.09 - Stock Titan
Insider Buy: Can SYFPRA maintain sales growthAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bull Run: Can Spyre Therapeutics Inc lead its sector in growth2025 Geopolitical Influence & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aug Final Week: Is FORL a defensive stockChart Signals & Accurate Trade Setup Notifications - baoquankhu1.vn
Big Picture: How does Spyre Therapeutics Inc score in quality rankings2025 Price Action Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Spyre Therapeutics IncSkyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule - TradingView
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Innovative Biotech with 86.51% Upside Potential - DirectorsTalk Interviews
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - Улправда
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - Улправда
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - Улправда
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages - Defense World
Aeglea BioTherapeutics Announces Grants of Inducement Awards - Quantisnow
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares - Investing.com Canada
Institution Moves: Is Spyre Therapeutics Inc stock a contrarian buy2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):